<DOC>
	<DOCNO>NCT00601770</DOCNO>
	<brief_summary>The objective investigate virological ( HCV-RNA ) responses follow biweekly immunization IC41 . Treatment phase 14 week , total study duration include follow-up period 38 week .</brief_summary>
	<brief_title>Virological Response Study HCV Vaccine IC41</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Written inform consent obtain prior study entry Patients chronic hepatitis C ; genotype 1 Treatment naive patient Male Female , 18 55 year Presence HLAA2 marker Mentally healthy No clinically relevant pathological finding investigation screen Treatment naive patient chronic Hepatitis C genotype 1 Positive result HIV , HBsAg HAVAg ( IgM ) Other cause chronic hepatitis History autoimmune diseases Previous vaccination prophylactic therapeutic Hepatitis C vaccine ( clinical study ) Active passive vaccination 4 week entire study period Decompensated liver disease History severe hypersensitivity reaction anaphylaxis Known allergic reaction one component vaccine Imiquimod cream Clinically significant disease , opinion Investigator , might lead frequent hospitalization/medical attendance Malignancies Immunosuppressive therapy Pregnancy , lactation breastfeeding Unwillingness practice appropriate contraception Participation another study investigational drug within 1 month prior enrolment entire study period Patients , opinion Investigator , might able comply study protocol ( e.g . : Drug addiction , alcoholism )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>